Hematological Side Effects Management of Paclitaxel - Carboplatin Chemotherapy in Lung Cancer
(1) RSUP Dr. M. Djamil, Padang, West Sumatera, Indonesia
(2) RSUP Dr. M. Djamil, Padang, West Sumatera, Indonesia
(*) Corresponding Author
Abstract
Background: Paclitaxel-carboplatin chemotherapy can cause hema-tological disorders. This regiment's hematological side effects include anemia, neutropenia, and thrombocytopenia. Data showed this regiment side effect occurs with grade iii/iv toxicity anemia, grade III/IV anemia by 41%, neutropenia (78%), and thrombocytopenia (41%). This hema-tological disorder occurs in bone marrow-producing areas due to chemotherapy. Each hematological disorder requires separate interven-tion.
Case Presentation: A 54-year-old woman was diagnosed with a progressive disease of left lung adenocarcinoma (Exon 21 mutation) with TKI and received paclitaxel-carboplatin chemotherapy. The patient experienced side effects of anemia, neutropenia, and thrombocytopenia. Anemia was treated with PRC transfusion, neutropenia corrected with Filgrastim, and thrombocytopenia with platelet transfusion. Chemo-therapy was discontinued after five cycles because the Thrombo-cytopenia condition did not improve.
Conclusion: Hematological parameters are essential in preparing for lung cancer chemotherapy. Uncorrectable hematological disorders lead to discontinuation of chemotherapyKeywords
Full Text:
PDFReferences
REFFERENCE
Charles A, Dewayani BM, Sahiratmadja E, Winarno GNA, Susanto H. Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients. Universa Med. 2016;35(3):165.
Shafiq M, Venkateshiah S. Hematologic abnormalities associated with lung carcinoma. Respir Care. 2011;56(4):523–6.
Yuliandra Y, Nasif H, Ermayanti S, Sulistyowati L, Juwita DA. Hematologic Toxicities of Chemotherapy in Lung Cancer Patients: A Retrospective Study in Dr. M. Djamil Hospital Padang, Indonesia. Indones J Clin Pharm. 2019;8(2):129–31.
Grandgirard J, Poinsot D, Krespi L, Nénon JP, Cortesero AM. Costs of secondary parasitism in the facultative hyperparasitoid Pachycrepoideus dubius: Does host size matter? Entomol Exp Appl. 2002;103(3):239–48.
Leong SS, Wee J, Tay MH, Toh CK, Tan SB, Thng CH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: A phase II trial using a triplet combination. Cancer. 2005;103(3):569–75.
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, et al. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer [Internet]. 2011;105(3):360–5. Available from: http://dx.doi.org/10.1038/bjc.2011.256
Shukla P, Singh R. Potential pharmacological interventions against hematotoxicity: An overview. Expert Rev Hematol. 2015;8(4):505–14.
Muñoz-Langa J, De Castro J, Gascó P, Sanchez A, Esteban E, Gasent JM, et al. Chemotherapy-associated anemia in patients with lung cancer: An epidemiological, retrospective and multicenter study. Futur Oncol. 2015;11(11):1665–74.
Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282–94.
Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs. 2015;26(10):1054–60.
Chabner BA, Amrein PC, Druker B. Chemotherapy of Neoplastic Diseases. In: Goodman and Gilman ’s The Pharmacological Basis of Therapeutics New York: The McGraw-Hill Companies; 2011. p. 1854–921.
Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, et al. Cancer- and Chemotherapy-Induced Anemia. J Natl Compr Cancer Netw. 2012;10(5):628–53.
Perhimpunan Dokter Paru Indonesia. Kanker Paru : Pedoman Diagnosis & Penatalaksanaan di Indonesia. 2018. p. 49–50.
Chen C, Song Z, Wang W, Zhou J. Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer. Mol Clin Oncol. 2021;14(3):1–7.
Hoffbrand A, Moss P PJ. Essential Haematology. 5th ed. In: Victoria: Blackwell Publishing. 2006. p. 115–89.
Usami E, Kimura M, Iwai M, Takenaka S, Teramachi H, Yoshimura T. Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. Mol Clin Oncol. 2016;591–6.
Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73(1):106–14.
Anderson PO, Knoben JE, Troutman WG. Handbook of clinical drug data. 10th edition, McGraw-Hill, San Diego, CA. 2002;115–89.
Syahruddin E MN, Hudoyo A. Efficacy and toxicity chemotherapy with cisplatin + etoposide regimen in advanced stage non-small cell lung cancer. J Respir Indo. 2012;5:25–35.
Kurtin S. Myeloid Toxicity of Cancer Treatment. J Adv Pr Oncol. 2012;209–24.
De Silva E, Kim H. Drug-induced thrombocytopenia: Focus on platelet apoptosis. Chem Biol Interact. 2018;284:1–11.
Febriani A, Rahmawati Y. Efek Samping Hematologi Akibat Kemoterapi dan Tatalaksananya. J Respirasi. 2019;5(1):22–5.
Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. Int J Clin Transfus Med. 2018;Volume 6:21–31.
Anderson W. Guidelines for the management of chemotherapy and systemic anticancer therapy induced toxicities within primary care. Northen Cancer Alliace. 2018;(June 2018):0–21.
Article Metrics
Abstract view : 159 timesPDF - 43 times
DOI: https://doi.org/10.26714/magnamed.10.1.2023.129-140
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Indexed by
MAGNA MEDIKA by APKKM is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.